Canada Pharmacy Seeks Faster Cure for Chronic Myeloid Leukemia

A commentary published in the Canadian Medical Association Journal reveals chronic myeloid leukemia (CML) has not been completely eradicated in patients. More efforts must be put in, suggests our Canadian pharmacy, to find a cure that addresses all symptoms in patients irrespective of age or other medical complications. Experts from the Anderson Cancer Centre in Houston appreciate the pace at which a cure has been found. Experts feel research efforts are on track to find medical solutions for specific groups of people affected by leukemia.

Individuals over the age of 60 years generally develop CML more frequently, and the rate of incidence increases in the elderly. People generally buy Gleevec for treatment of the disease, especially as a first-line therapy. Experts are of the opinion, however, limited structured information exist regarding progress of the disease in older people. Continuous research is therefore needed to record information on symptoms and complications arising in people over the age of 60 years.

Imatinib has been instrumental in helping physicians make accurate prognosis with regard to CML patients. Experts found the Sokal and Euro risk scores inaccurate in determining outcome and response rates for long-term treatment of CML. Long-term survival rates in the elderly is a major factor to consider when implementing treatment plans. Prescription drugs are very effective now, but specific information related to different age groups must be accumulated in order to predict how patients would respond to medication and increase chances of survival.

Our generic Canadian pharmacy points out tremendous progress have been made to improve treatment options. For example, survival rate on developing CML in the 60s was approximately 3 to 5 years but has increased to 90% over the years. Effective prescription drugs enable around 60% people to recover from CML, but 15% are likely to have drug resistance even if several prescription drugs are combined based on individual needs.

Adherence to treatment is one aspect the medical fraternity has to outline in clear terms, so patients are aware of what needs to be done to increase response rates to medication. Research into new therapies has to be initiated with focus on providing long-term cure. Data accumulation concerning elderly patients with focus on recording improvement in patients over several years will enhance advancements made in prescription drug technology to help patients survive longer.

Nearly 20 percent suffer from leukemia in developed countries across Europe and the United States. Current pharmaceutical advancement has found a solution to treat abnormal chromosomes, but drug resistance is a major issue experts have to deal with. Constantly monitoring different stages of the disease helps identify the period when prescription drugs fail to stop progression of CML.

Physicians are able to help patients in some cases. However, faulty fusion of genes leading to Philadelphia chromosome has created complications that need urgent solutions. Our Canadian pharmacy encourages research targeting different proteins responsible for changing outcome rates based on improving therapeutic value in developed prescription drugs. Some patients may not benefit initially, but further research aimed at targeting specific groups of people will help realize better results.